CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $5.4167.

A number of equities research analysts recently weighed in on CTMX shares. Oppenheimer started coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They issued an “outperform” rating and a $7.00 price target on the stock. Barclays started coverage on CytomX Therapeutics in a research note on Wednesday, September 17th. They issued an “overweight” rating and a $3.50 price target on the stock. Finally, Cantor Fitzgerald started coverage on CytomX Therapeutics in a research note on Monday. They issued an “overweight” rating and a $6.00 price target on the stock.

CytomX Therapeutics Stock Up 2.4%

Shares of CytomX Therapeutics stock opened at $2.11 on Wednesday. CytomX Therapeutics has a 12-month low of $0.40 and a 12-month high of $3.10. The stock has a market cap of $347.96 million, a P/E ratio of 3.77 and a beta of 2.18. The business’s 50 day moving average is $2.14 and its 200-day moving average is $1.74.

Institutional Investors Weigh In On CytomX Therapeutics

Large investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its position in CytomX Therapeutics by 1.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 720,020 shares of the biotechnology company’s stock worth $1,634,000 after buying an additional 8,566 shares during the period. Aspire Growth Partners LLC increased its position in CytomX Therapeutics by 10.8% during the 2nd quarter. Aspire Growth Partners LLC now owns 102,254 shares of the biotechnology company’s stock worth $232,000 after buying an additional 10,000 shares during the period. Vanguard Personalized Indexing Management LLC increased its position in CytomX Therapeutics by 63.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 28,966 shares of the biotechnology company’s stock worth $66,000 after buying an additional 11,258 shares during the period. Invesco Ltd. bought a new position in CytomX Therapeutics during the 2nd quarter worth $32,000. Finally, Pursue Wealth Partners LLC bought a new position in CytomX Therapeutics during the 2nd quarter worth $33,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.